Arca
Skip to content
Tools
Tools

Hepatitis C

Drug research and approvals for hepatitis C: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 20, 2026, 50 studies of hepatitis C are recruiting on ClinicalTrials.gov, Health Canada has authorized 75 drug trials for it since 2013, FDA has 11 approved and 2 open orphan designations naming it, and the EU has 7 authorised medicines for it.

  • Recruiting worldwide: 50
  • Trials authorized in Canada: 75
  • FDA orphan approvals: 11
  • EU medicines: 7

Recruiting now

Newest posted first, of 50 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 6

  • SofosbuvirRNA-directed RNA polymerase inhibitor
  • RitonavirHuman immunodeficiency virus type 1 protease inhibitor
  • ParitaprevirHepatitis C virus serine protease, NS3/NS4A inhibitor
  • OmbitasvirNonstructural protein 5A inhibitor
  • DasabuvirRNA-directed RNA polymerase inhibitor
  • LedipasvirNonstructural protein 5A inhibitor

Phase 3 12 of 32

Phase 2 12 of 44

Phase 1 or earlier 12 of 49

How its trials ended

2,345 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 787 whose ending is known, 61% met their primary endpoint, 4% missed it and 35% stopped early.

  • Completed, result not reported1,16350%
  • Met its primary endpoint47720%
  • Status unknown28012%
  • Stopped: other or unclear1637%
  • Ongoing1155%
  • Stopped: enrollment or feasibility673%
  • Missed its primary endpoint341%
  • Stopped: sponsor or business decision181%
  • Stopped: lack of efficacy131%
  • Stopped: funding10<1%
  • Stopped: safety5<1%

Trials authorized in Canada

The 10 newest of 75; search them all in Canada trials
May 26, 2025Phase 3, randomized, controlled, open-label study to compare the efficacy and safety of bemnifosbuvir-ruzasvir fixed-dose combination (bem/rzr fdc) versus…Bemnifosbuvir (AT-527)-ruzasvir (AT-038)Atea Pharmaceuticals IncClosed
May 10, 2023A phase 2 open-label study to assess the safety and efficacy of bemnifosbuvir (BEM) and ruzasvir (RZR) in subjects with chronic hepatitis C virus (HCV)…Bemnifosbuvir (AT-527)/ Ruzasvir (AT-038)Atea Pharmaceuticals IncClosed
Sep 9, 2022Safety, tolerability, and outcomes of velpatasvir/sofosbuvir in treatment of chronic hepatitis C virus during pregnancy (STORC):a single-arm, single-center,…Sofosbuvir-velpatasvirUniversity Health NetworkOngoing
Mar 30, 2022Randomised, open-label and parallel group trial to investigate the effects of oral bi 685509 alone or in combination with empagliflozin on portal hypertension…Bi 685509 / EmpagliflozinBoehringer Ingelheim (Canada) Ltd LteePending
Jul 15, 2021A multicenter, single-arm prospective study to evaluate safety and efficacy of gle/pib 8-week treatment in adults and adolescents with acute hepatitis C virus…Glecaprevir (ABT-493)-pibrentasvir (ABT-530)AbbVieClosed
Jul 20, 2017A phase 3 clinical study to evaluate the efficacy and safety of the combination regimen of MK-3682B (grazoprevir/ruzasvir/uprifosbuvir) in participants with…MK-3682B [grazoprevir (MK-5172)-ruzasvir (MK-8408)-uprifosbuvir (MK-3682)]Merck & Co. (MSD)Pending
Jul 20, 2017A phase II, randomized, open-label clinical trial to study the efficacy and safety of the combination regiment of MK-3682B (MK-5172 + MK-3682 + MK-8408 fixed…Grazoprevir (MK-5172)-ruzasvir(MK-8408)-uprifosbuvir (MK-3682)Merck & Co. (MSD)Ongoing
Jul 17, 2017A single arm, open label, multicenter study to evaluate the efficacy and safety of glecaprevir(GLE)/pibrentasvir(PIB) in treatment naïve adults with chronic…Glecaprevir (ABT-493)-pibrentasvir (ABT-530)AbbVieClosed
May 9, 2017A single arm, open-label study to evaluate the efficacy and safety of glecaprevir (GLE)/pibrentasvir (PIB) in treatment naïve adults with chronic hepatitis C…Glecaprevir (ABT-493)-pibrentasvir (ABT-530)AbbVieClosed
Apr 11, 2017A randomised study of interferon-free treatment for recently acquired hepatitis C in people who inject drugs and people with HIV coinfection (REACT)Sofosbuvir-velpatasvirUniversity of New South WalesClosed

FDA orphan designations

Approved first, then open designations, newest first
Jun 10, 2021EpclusaTreatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6…Gilead Sciences, Inc.Approved
Jun 10, 2021MavyretTreatment of adult and pediatric patients 3 years and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection…AbbVie, Inc.Approved
Mar 19, 2020EpclusaEPCLUSA is indicated for the treatment of adults and pediatric patients 6 years of age and older or weighing at least 17 kg with chronic…Gilead Sciences, Inc.Approved
Aug 28, 2019SovaldiSOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without…Gilead Sciences, Inc.Approved
Aug 28, 2019SovaldiSOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without…Gilead Sciences, Inc.Approved
Aug 28, 2019HarvoniHARVONI is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV)…Gilead Sciences, Inc.Approved
Aug 28, 2019HarvoniHARVONI is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV)…Gilead Sciences, Inc.Approved
Apr 30, 2019MavyretMAVYRET is indicated for the treatment of adult and pediatric patients 12 years and older or weighing at least 45 kg with chronic hepatitis…AbbVie, Inc.Approved
Apr 7, 2017SovaldiTreatment of chronic HCV genotype 2 or 3 infection in pediatric patients 12 years of age and older or weighing at least 35 kg without…Gilead Sciences, Inc.Approved
Apr 7, 2017HarvoniTreatment of pediatric patients 12 years of age and older or weighing at least 35 kg with chronic hepatitis C virus genotype 1, 4, 5, or 6…Gilead Sciences, Inc.Approved
Jul 29, 2003RebetolTreatment of chronic hepatitis C among previously untreated pediatric patients at least three years of age or older.Schering CorporationApproved
Jul 16, 2015ombitasvir/paritaprevir/ritonavir and dasabuvirTreatment of pediatric patients with hepatitis C virus infection (0 through 16 years of age)Abbvie, Inc.Designated
Feb 17, 2012Silibinin-C-2',3-dihydrogensuccinate, disodium saltPrevention of recurrent hepatitis C in liver transplant patientsViatris Specialty LLCDesignated

Medicines authorised in the EU

Newest first
Jul 26, 2017MaviretGlecaprevir; pibrentasvirAbbVie Deutschland GmbH & Co. KGEMA ↗
Jul 26, 2017VoseviSofosbuvir; velpatasvir; voxilapreviGilead Sciences Ireland UCEMA ↗
Jul 22, 2016ZepatierElbasvir; grazoprevirMerck Sharp & Dohme B.V.EMA ↗
Jul 6, 2016EpclusaSofosbuvir; velpatasvirGilead Sciences Ireland UCEMA ↗
Nov 17, 2014HarvoniLedispavir; sofosbuvirGilead Sciences Ireland UCEMA ↗
Jan 16, 2014SovaldiSofosbuvirGilead Sciences Ireland UCEMA ↗
Jun 20, 2002PegasysPeginterferon alfa-2apharmaand GmbHEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.